
Quarterly report 2024-Q3
added 11-07-2024
Avinger Revenue 2011-2026 | AVGR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Avinger
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.65 M | 8.27 M | 10.1 M | 8.76 M | 9.13 M | 7.92 M | 9.93 M | 19.2 M | 10.7 M | 11.2 M | 13 M | 8.56 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.2 M | 7.65 M | 10.4 M |
Quarterly Revenue Avinger
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.65 M | 1.85 M | 1.86 M | - | 1.82 M | 2.04 M | 1.89 M | - | 2.25 M | 2.13 M | 1.89 M | - | 2.37 M | 2.8 M | 2.56 M | - | 2.3 M | 1.47 M | 2.26 M | - | 2.41 M | 2.32 M | 1.84 M | - | 2.02 M | 2.06 M | 1.81 M | - | 2.07 M | 2.46 M | 3.49 M | 4.68 M | 5.32 M | 4.68 M | 4.54 M | 2.86 M | 2.72 M | 3.05 M | 2.09 M | 3.07 M | 2.63 M | 3.39 M | 2.12 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.32 M | 1.47 M | 2.58 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 7.25 | -8.17 % | $ 521 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M | ||
|
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.97 | - | $ 137 M | ||
|
Alphatec Holdings
ATEC
|
612 M | $ 13.48 | -4.13 % | $ 1.93 B | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 4.08 | 0.37 % | $ 152 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 299.07 | -2.23 % | $ 8.44 B | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 41.06 | -3.54 % | $ 6.12 K | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
16.7 B | $ 78.26 | 3.65 % | $ 115 B | ||
|
Abbott Laboratories
ABT
|
42 B | $ 109.11 | 0.84 % | $ 190 B | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
ClearPoint Neuro
CLPT
|
31.4 M | $ 12.43 | -6.61 % | $ 336 M | ||
|
CONMED Corporation
CNMD
|
1.31 B | $ 40.63 | 1.75 % | $ 1.25 B | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
64 M | $ 28.95 | -0.96 % | $ 245 M | ||
|
InMode Ltd.
INMD
|
358 M | $ 14.77 | -1.66 % | $ 1.17 B | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Profound Medical Corp.
PROF
|
7.2 M | $ 6.35 | -6.89 % | $ 180 M | ||
|
Align Technology
ALGN
|
4 B | $ 176.77 | 9.59 % | $ 13.2 B | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.54 | 0.11 % | $ 122 M | ||
|
Globus Medical
GMED
|
2.52 B | $ 87.55 | 0.56 % | $ 11.9 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 10.94 | -1.26 % | $ 842 M | ||
|
Establishment Labs Holdings
ESTA
|
166 M | $ 66.7 | -3.52 % | $ 1.88 B | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.45 | 0.69 % | $ 23.4 M | ||
|
IRadimed Corporation
IRMD
|
73.2 M | $ 94.23 | 0.4 % | $ 1.19 B | ||
|
Integer Holdings Corporation
ITGR
|
1.72 B | $ 85.94 | 0.49 % | $ 2.89 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.67 | 0.3 % | $ 36.5 M | ||
|
OrthoPediatrics Corp.
KIDS
|
205 M | $ 16.64 | -1.54 % | $ 384 M |